TherapeuticsMD, Inc. (TXMD) stock
TXMDNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 11, 2026Score 12/3030% below fair value
$1.82−0.03 (-1.62%)
Close on Nov 12, 2026Market cap $21.07MP/E –Yield –
TherapeuticsMD EPS
Diluted earnings per share is net income divided by the share count including options and convertible securities.
TherapeuticsMD's EPS for the twelve months ending Jun 30, 2026 was -$0.02. For fiscal 2025 it was -$0.05. The highest annual figure on record is $11.96 in fiscal 2022.
Annual eps
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$0.05 | – |
| FY2024 | Dec 31, 2024 | -$0.19 | – |
| FY2023 | Dec 31, 2023 | -$0.99 | -108.3% |
| FY2022 | Dec 31, 2022 | $11.96 | – |
| FY2021 | Dec 31, 2021 | -$21.66 | – |
| FY2020 | Dec 31, 2020 | -$33.50 | – |
| FY2019 | Dec 31, 2019 | -$36.00 | – |
| FY2018 | Dec 31, 2018 | -$29.50 | – |
| FY2017 | Dec 31, 2017 | -$18.50 | – |
| FY2016 | Dec 31, 2016 | -$23.00 | – |
| FY2015 | Dec 31, 2015 | -$24.50 | – |
| FY2014 | Dec 31, 2014 | -$18.00 | – |
| FY2013 | Dec 31, 2013 | -$11.00 | – |
| FY2012 | Dec 31, 2012 | -$19.00 | – |
| FY2011 | Dec 31, 2011 | -$10.50 | – |
Quarterly eps
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $0.01 | -80.0% |
| Q1 FY2026 | Mar 31, 2026 | $0.01 | – |
| Q4 FY2025 | Dec 31, 2025 | -$0.05 | -350.0% |
| Q3 FY2025 | Sep 30, 2025 | $0.01 | – |
| Q2 FY2025 | Jun 30, 2025 | $0.05 | – |
| Q1 FY2025 | Mar 31, 2025 | -$0.06 | – |
| Q4 FY2024 | Dec 31, 2024 | $0.02 | – |
| Q3 FY2024 | Sep 30, 2024 | -$0.05 | – |
| Q2 FY2024 | Jun 30, 2024 | -$0.09 | – |
| Q1 FY2024 | Mar 31, 2024 | -$0.06 | -100.8% |
| Q3 FY2023 | Sep 30, 2023 | -$0.32 | – |
| Q2 FY2023 | Jun 30, 2023 | -$0.24 | -101.9% |
| Q1 FY2023 | Mar 31, 2023 | -$0.37 | – |
| Q4 FY2022 | Dec 31, 2022 | $7.17 | – |
| Q3 FY2022 | Sep 30, 2022 | -$3.13 | – |
| Q2 FY2022 | Jun 30, 2022 | $12.83 | – |
| Q1 FY2022 | Mar 31, 2022 | -$5.70 | – |
| Q4 FY2021 | Dec 31, 2021 | -$5.00 | – |
| Q3 FY2021 | Sep 30, 2021 | -$5.62 | – |
| Q2 FY2021 | Jun 30, 2021 | -$5.41 | – |
| Q1 FY2021 | Mar 31, 2021 | -$5.67 | – |
| Q4 FY2020 | Dec 31, 2020 | -$7.50 | – |
| Q3 FY2020 | Sep 30, 2020 | -$6.00 | – |
| Q2 FY2020 | Jun 30, 2020 | -$9.50 | – |
| Q1 FY2020 | Mar 31, 2020 | -$10.50 | – |
| Q4 FY2019 | Dec 31, 2019 | -$9.50 | – |
| Q3 FY2019 | Sep 30, 2019 | -$6.50 | – |
| Q2 FY2019 | Jun 30, 2019 | -$11.50 | – |
| Q1 FY2019 | Mar 31, 2019 | -$8.00 | – |
| Q4 FY2018 | Dec 31, 2018 | -$8.50 | – |
| Q3 FY2018 | Sep 30, 2018 | -$8.00 | – |
| Q2 FY2018 | Jun 30, 2018 | -$7.50 | – |
| Q1 FY2018 | Mar 31, 2018 | -$5.50 | – |
| Q4 FY2017 | Dec 31, 2017 | -$5.00 | – |
| Q3 FY2017 | Sep 30, 2017 | -$3.50 | – |
| Q2 FY2017 | Jun 30, 2017 | -$5.00 | – |
| Q1 FY2017 | Mar 31, 2017 | -$5.50 | – |
| Q4 FY2016 | Dec 31, 2016 | -$6.00 | – |
| Q3 FY2016 | Sep 30, 2016 | -$6.50 | – |
- Revenue
- Gross Profit
- Operating Income
- Net Income
- EBITDA
- Free Cash Flow
- Operating Cash Flow
- R&D Expenses
- Gross Margin
- Operating Margin
- Profit Margin
- Total Debt
- Cash
- Total Assets
- Shares Outstanding
- Market Cap
- Enterprise Value
- PE Ratio
- Price to Sales Ratio
- Price to Book Ratio
- EV/EBITDA
- Price to Free Cash Flow
- All statistics
See a number that looks wrong?